Ferrajoli, Alessandra
Ferrajoli, Alessandra
DIPARTIMENTO DI MEDICINA CLINICA E MOLECOLARE
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
2020 Dinardo, Cd; Maiti, A; Rausch, Cr; Pemmaraju, N; Naqvi, K; Daver, Ng; Kadia, Tm; Borthakur, G; Ohanian, M; Alvarado, Y; Issa, Gc; Montalban-Bravo, G; Short, Nj; Yilmaz, M; Bose, P; Jabbour, Ej; Takahashi, K; Burger, Ja; Garcia-Manero, G; Jain, N; Kornblau, Sm; Thompson, Pa; Estrov, Z; Masarova, L; Sasaki, K; Verstovsek, S; Ferrajoli, A; Weirda, Wg; Wang, Sa; Konoplev, S; Chen, Zn; Pierce, Sa; Ning, J; Qiao, W; Ravandi, F; Andreeff, M; Welch, Js; Kantarjian, Hm; Konopleva, My
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
2024 Hampel, Paul J.; Swaminathan, Mahesh; Rogers, Kerry A.; Parry, Erin M.; Burger, Jan A.; Davids, Matthew S.; Ding, Wei; Ferrajoli, Alessandra; Hyak, Jonathan M.; Jain, Nitin; Kenderian, Saad S.; Wang, Yucai; Wierda, William G.; Woyach, Jennifer A.; Parikh, Sameer A.; Thompson, Philip A.
A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale
2023 Gordon, Mj; Duan, Zg; Zhao, H; Nastoupil, L; Ferrajoli, A; Danilov, Av; Giordano, Sh
A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure
2019 Swaminathan, M; Borthakur, G; Kadia, Tm; Ferrajoli, A; Alvarado, Y; Pemmaraju, N; Bodden, K; Yearby, B; Konopleva, M; Khoury, J; Bueso-Ramos, C; Garcia-Manero, G; Dinardo, Cd
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
2023 Jain, N; Senapati, J; Thakral, B; Ferrajoli, A; Thompson, P; Burger, J; Basu, S; Kadia, T; Daver, N; Borthakur, G; Konopleva, M; Pemmaraju, N; Parry, E; Wu, Cj; Khoury, J; Bueso-Ramos, C; Garg, N; Wang, Xm; Lopez, W; Ayala, A; O'Brien, S; Kantarjian, H; Keating, M; Allison, J; Sharma, P; Wierda, W
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis
2019 Bose, P; Swaminathan, M; Pemmaraju, N; Ferrajoli, A; Jabbour, Ej; Daver, Ng; Dinardo, Cd; Alvarado, Y; Yilmaz, M; Huynh-Lu, J; Qiao, W; Wang, Xm; Matamoros, A; Zhou, Ls; Pierce, S; Schroeder, Kd; Kantarjian, Hm; Verstovsek, S
A Phase 2 Study of Yttrium-90 Ibritumomab Tiuxetan (Zevalin) in Patients With Chronic Lymphocytic Leukemia
2009 Jain, N; Wierda, W; Ferrajoli, A; Wong, F; Lerner, S; Keating, M; O'Brien, S
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia
2010 Kadia, Tm; Yang, H; Ferrajoli, A; Maddipotti, S; Schroeder, C; Madden, Tl; Holleran, Jl; Egorin, Mj; Ravandi, F; Thomas, Da; Newsome, W; Sanchez-Gonzalez, B; Zwiebel, Ja; Espinoza-Delgado, I; Kantarjian, Hm; Garcia-Manero, G
A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia
2015 Strati, P; Tong, Wg; Vitale, C; Wierda, Wg; O'Brien, S; Brown, Jr; Weng, Wk; Kipps, T; Keating, Mj; Ferrajoli, A
A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia
2019 Paul, S; Jain, N; Ferrajoli, A; O'Brien, S; Burger, J; Keating, M; Wierda, W
A phase two study of high dose blinatumomab in Richter's syndrome
2022 Thompson, Pa; Jiang, Xl; Banerjee, P; Basar, R; Garg, N; Chen, K; Kaplan, M; Nandivada, V; Cortes, Akn; Ferrajoli, A; Keating, Mj; Peterson, Cb; Andreeff, M; Rezvani, K; Wierda, Wg
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
2018 Abou Dalle, I; Cortes, Je; Pinnamaneni, P; Lamothe, B; Duque, Ad; Randhawa, J; Pemmaraju, N; Jabbour, E; Ferrajoli, A; Wierda, Wg; Estrov, Z; Konopleva, M; Ravandi, F; Alvarado, Y; Borthakur, G; Gandhi, V; Kantarjian, Hm
A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia
2016 Randhawa, Jk; Ferrajoli, A
A Two- Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia
2011 Schweighofer, Cd; Coombes, Kr; Barron, Ll; Diao, Lx; Newman, Rj; Ferrajoli, A; O'Brien, S; Wierda, Wg; Luthra, R; Medeiros, Lj; Keating, Mj; Abruzzo, Lv
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
2025 Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Patel, Krish; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Hughes, Marie; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Follows, George; Walker, Patricia; Ghia, Paolo; Janssens, Ann; Byrd, John C; Ferrant, Emmanuelle; Ferrajoli, Alessandra; Wierda, William G; Wachira, Catherine Wangui; Suterwala, Batul T; Miranda, Paulo; Munugalavadla, Veerendra; Wun, Chuan-Chuan; Woyach, Jennifer A
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors
2020 Strati, P; Schlette, Ej; Soto, Lms; Duenas, De; Sivina, M; Kim, E; Keating, Mj; Wierda, Wg; Ferrajoli, A; Kantarjian, H; Estrov, Z; Jain, N; Thompson, Pa; Wistuba, Ii; Burger, Ja
Activation of the B-cell receptor successively activates NF-kappa B and STAT3 in chronic lymphocytic leukemia cells
2017 Rozovski, U; Harris, Dm; Li, P; Liu, Zm; Jain, P; Veletic, I; Ferrajoli, A; Burger, J; Thompson, P; Jain, N; Wierda, W; Keating, Mj; Estrov, Z
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia
2018 Assi, R; Garcia-Manero, G; Ravandi, F; Borthakur, G; Daver, Ng; Jabbour, E; Burger, J; Estrov, Z; Dinardo, Cd; Alvarado, Y; Hendrickson, S; Ferrajoli, A; Wierda, W; Cortes, J; Kantarjian, Hm; Kadia, Tm
Adjunct Hyperbaric Oxygen Therapy for Refractory Infections in Patients with Hematologic Malignancies: A Single-Center Retrospective Study
2026 Kim, Kunhwa; Kontoyiannis, Dimitrios P.; Ahaneku, Hycienth; Mccue, Deborah; Adachi, Javier; Ferrajoli, Alessandra
Alemtuzumab by Continuous Intravenous Infusion Followed by Subcutaneous Injection Plus Rituximab in the Treatment of Patients With Chronic Lymphocytic Leukemia Recurrence
2010 Faderl, S; Ferrajoli, A; Wierda, W; O'Brien, S; Lerner, S; Keating, Mj
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial | 2020 | Dinardo, Cd; Maiti, A; Rausch, Cr; Pemmaraju, N; Naqvi, K; Daver, Ng; Kadia, Tm; Borthakur, G; Ohanian, M; Alvarado, Y; Issa, Gc; Montalban-Bravo, G; Short, Nj; Yilmaz, M; Bose, P; Jabbour, Ej; Takahashi, K; Burger, Ja; Garcia-Manero, G; Jain, N; Kornblau, Sm; Thompson, Pa; Estrov, Z; Masarova, L; Sasaki, K; Verstovsek, S; Ferrajoli, A; Weirda, Wg; Wang, Sa; Konoplev, S; Chen, Zn; Pierce, Sa; Ning, J; Qiao, W; Ravandi, F; Andreeff, M; Welch, Js; Kantarjian, Hm; Konopleva, My | |
| A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia | 2024 | Hampel, Paul J.; Swaminathan, Mahesh; Rogers, Kerry A.; Parry, Erin M.; Burger, Jan A.; Davids, Matthew S.; Ding, Wei; Ferrajoli, Alessandra; Hyak, Jonathan M.; Jain, Nitin; Kenderian, Saad S.; Wang, Yucai; Wierda, William G.; Woyach, Jennifer A.; Parikh, Sameer A.; Thompson, Philip A. | |
| A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale | 2023 | Gordon, Mj; Duan, Zg; Zhao, H; Nastoupil, L; Ferrajoli, A; Danilov, Av; Giordano, Sh | |
| A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure | 2019 | Swaminathan, M; Borthakur, G; Kadia, Tm; Ferrajoli, A; Alvarado, Y; Pemmaraju, N; Bodden, K; Yearby, B; Konopleva, M; Khoury, J; Bueso-Ramos, C; Garcia-Manero, G; Dinardo, Cd | |
| A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL | 2023 | Jain, N; Senapati, J; Thakral, B; Ferrajoli, A; Thompson, P; Burger, J; Basu, S; Kadia, T; Daver, N; Borthakur, G; Konopleva, M; Pemmaraju, N; Parry, E; Wu, Cj; Khoury, J; Bueso-Ramos, C; Garg, N; Wang, Xm; Lopez, W; Ayala, A; O'Brien, S; Kantarjian, H; Keating, M; Allison, J; Sharma, P; Wierda, W | |
| A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis | 2019 | Bose, P; Swaminathan, M; Pemmaraju, N; Ferrajoli, A; Jabbour, Ej; Daver, Ng; Dinardo, Cd; Alvarado, Y; Yilmaz, M; Huynh-Lu, J; Qiao, W; Wang, Xm; Matamoros, A; Zhou, Ls; Pierce, S; Schroeder, Kd; Kantarjian, Hm; Verstovsek, S | |
| A Phase 2 Study of Yttrium-90 Ibritumomab Tiuxetan (Zevalin) in Patients With Chronic Lymphocytic Leukemia | 2009 | Jain, N; Wierda, W; Ferrajoli, A; Wong, F; Lerner, S; Keating, M; O'Brien, S | |
| A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia | 2010 | Kadia, Tm; Yang, H; Ferrajoli, A; Maddipotti, S; Schroeder, C; Madden, Tl; Holleran, Jl; Egorin, Mj; Ravandi, F; Thomas, Da; Newsome, W; Sanchez-Gonzalez, B; Zwiebel, Ja; Espinoza-Delgado, I; Kantarjian, Hm; Garcia-Manero, G | |
| A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia | 2015 | Strati, P; Tong, Wg; Vitale, C; Wierda, Wg; O'Brien, S; Brown, Jr; Weng, Wk; Kipps, T; Keating, Mj; Ferrajoli, A | |
| A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia | 2019 | Paul, S; Jain, N; Ferrajoli, A; O'Brien, S; Burger, J; Keating, M; Wierda, W | |
| A phase two study of high dose blinatumomab in Richter's syndrome | 2022 | Thompson, Pa; Jiang, Xl; Banerjee, P; Basar, R; Garg, N; Chen, K; Kaplan, M; Nandivada, V; Cortes, Akn; Ferrajoli, A; Keating, Mj; Peterson, Cb; Andreeff, M; Rezvani, K; Wierda, Wg | |
| A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia | 2018 | Abou Dalle, I; Cortes, Je; Pinnamaneni, P; Lamothe, B; Duque, Ad; Randhawa, J; Pemmaraju, N; Jabbour, E; Ferrajoli, A; Wierda, Wg; Estrov, Z; Konopleva, M; Ravandi, F; Alvarado, Y; Borthakur, G; Gandhi, V; Kantarjian, Hm | |
| A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia | 2016 | Randhawa, Jk; Ferrajoli, A | |
| A Two- Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia | 2011 | Schweighofer, Cd; Coombes, Kr; Barron, Ll; Diao, Lx; Newman, Rj; Ferrajoli, A; O'Brien, S; Wierda, Wg; Luthra, R; Medeiros, Lj; Keating, Mj; Abruzzo, Lv | |
| Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN | 2025 | Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Patel, Krish; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Hughes, Marie; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Follows, George; Walker, Patricia; Ghia, Paolo; Janssens, Ann; Byrd, John C; Ferrant, Emmanuelle; Ferrajoli, Alessandra; Wierda, William G; Wachira, Catherine Wangui; Suterwala, Batul T; Miranda, Paulo; Munugalavadla, Veerendra; Wun, Chuan-Chuan; Woyach, Jennifer A | |
| Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors | 2020 | Strati, P; Schlette, Ej; Soto, Lms; Duenas, De; Sivina, M; Kim, E; Keating, Mj; Wierda, Wg; Ferrajoli, A; Kantarjian, H; Estrov, Z; Jain, N; Thompson, Pa; Wistuba, Ii; Burger, Ja | |
| Activation of the B-cell receptor successively activates NF-kappa B and STAT3 in chronic lymphocytic leukemia cells | 2017 | Rozovski, U; Harris, Dm; Li, P; Liu, Zm; Jain, P; Veletic, I; Ferrajoli, A; Burger, J; Thompson, P; Jain, N; Wierda, W; Keating, Mj; Estrov, Z | |
| Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia | 2018 | Assi, R; Garcia-Manero, G; Ravandi, F; Borthakur, G; Daver, Ng; Jabbour, E; Burger, J; Estrov, Z; Dinardo, Cd; Alvarado, Y; Hendrickson, S; Ferrajoli, A; Wierda, W; Cortes, J; Kantarjian, Hm; Kadia, Tm | |
| Adjunct Hyperbaric Oxygen Therapy for Refractory Infections in Patients with Hematologic Malignancies: A Single-Center Retrospective Study | 2026 | Kim, Kunhwa; Kontoyiannis, Dimitrios P.; Ahaneku, Hycienth; Mccue, Deborah; Adachi, Javier; Ferrajoli, Alessandra | |
| Alemtuzumab by Continuous Intravenous Infusion Followed by Subcutaneous Injection Plus Rituximab in the Treatment of Patients With Chronic Lymphocytic Leukemia Recurrence | 2010 | Faderl, S; Ferrajoli, A; Wierda, W; O'Brien, S; Lerner, S; Keating, Mj |